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Drug-Initiated Synthesis of Cladribine-Based 
Polymer Prodrug Nanoparticles: Biological 
Evaluation and Structure Activity 
Relationships 
Yinyin Bao, Elise Guégain and Julien Nicolas* 
Institut Galien Paris-Sud, CNRS UMR 8612, Univ Paris-Sud, Faculté de 
Pharmacie, 5 rue Jean-Baptiste Clément, 92290 Châtenay-Malabry, France 
*E-mail: julien.nicolas@u-psud.fr 
By using two reversible deactivation radical polymerization  
techniques, either nitroxide-mediated polymerization or 
reversible addition-fragmentation chain transfer 
polymerization, the “drug-initiated” approach was applied to 
cladribine (CdA) as an anticancer drug to synthesize small 
libraries of well-defined and self-stabilized CdA-based 
polymer prodrug nanoparticles, differing from the nature and 
the molar mass of the grown polymer, and the nature of the 
linker between CdA and the polymer, thus allowing structure-
cytotoxicity relationships to be determined. Their biological 
evaluation was investigated in vitro on L1210 cancer cells. 
The preparation of fluorescent CdA-based nanoparticles with 
excellent imaging ability was also reported by applying the 
“drug-initiated” approach to an aggregation-induced emission-
active dye.  
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Polymer prodrug nanocarriers have emerged as promising drug delivery 
systems that aim to circumvent the drawbacks of traditional drug-loaded 
nanocarriers (i.e., relying on a physical encapsulation of the drug into the 
polymer matrix) that usually exhibit significant limitations such as the “burst 
effect” and poor drug loadings.1,2 Polymer prodrug nanocarriers are obtained by 
covalent conjugation of drugs to a polymer chain by different approaches: (i) the 
post-functionalization of preformed polymers (“grafting to”);3–5 (ii) the 
polymerization of drug-conjugated monomers (“grafting through”)6–10 and (iii) 
the polymerization from drug-conjugated initiators (“drug initiated” or “grafting 
from”).11 In all cases, the resulting polymer prodrugs can be formulated into 
narrowly dispersed and stable nanoassemblies in aqueous solution. Recently, our 
group further developed the “drug-initiated” approach and applied it to vinyl 
polymers by reporting on the design of a gemcitabine (Gem)-conjugated 
alkoxyamine
12
 or chain transfer agent (CTA)
13,14
 to prepare well-defined 
polymer prodrug nanoparticles by either nitroxide-mediated radical 
polymerization (NMP) of isoprene or reversible addition−fragmentation chain 
transfer (RAFT) polymerization of squalenyl methacrylate (SqMA), 
respectively. The resulting self-stabilized, Gem-polymer prodrug nanoparticles 
exhibited great colloidal stability and significant in vitro and in vivo anticancer 
activity. Nevertheless, to further confirm the robustness and the versatility of the 
“drug-initiated” method from reversible-deactivation radical polymerization 
(RDRP) techniques, it was then applied to cladribine (CdA, 2-chloro-2’-
deoxyadenosine) as another anticancer drug. 
CdA, which can inhibit DNA synthesis, cause cell death and induce 
apoptosis, has been used as a first-line therapy in hairy cell leukemia and B-cell 
chronic lymphocytic leukemia.
15-19
 However, because of its rapid clearance from 
the bloodstream, CdA is administered at high doses, inducing cytotoxicity to 
resting and proliferating cells.
20-22
 Therefore, new strategies are needed to extend 
the circulation time and reduce the dose of CdA, as well as to induce higher 
toxicity to cancer cells compared to healthy cells. 
In this context, we report on the synthesis of different series of CdA-based 
polymer prodrugs, either by NMP or RAFT polymerization (Figure 1).
23,24
 The 
impact of the chemical structure of the polymer prodrugs on the cytotoxicity of 
the corresponding nanoparticles to cancer cells was systematically investigated 
by comparing: (i) two different linkages between the drug and the polymer; (ii) 
two different polymers and (iii) different polymer chain lengths. It enabled the 
establishment of preliminary structure–cytotoxicity relationships. In addition, 
we also prepared fluorescent polymer prodrug nanoparticles by growing a well-
defined polymer from a naphthalimide-based fluorophore with aggregation-
induced emission (AIE) activity,
25
 which enabled the successful tracking of 
CdA-polymer prodrug nanoparticles in living cells by a co-nanoprecipitation 
process.
26
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Figure 1. Synthesis of CdA-based polymer prodrug nanoparticles from “drug-
initiated” NMP of isoprene or RAFT polymerization of SqMA. 
Experimental Part 
Materials 
Cladribine was purchased from Sequoia Research Products, Limited (U.K.). 
4-Cyano-4-[(dodecylsulfanylthiocarbonyl)sulfanyl] pentanol (CDP) and 4-
cyano-4-[(dodecylsulfanylthiocarbonyl) sulfanyl]pentanoic acid (CDPA, 97%) 
were obtained from Sigma-Aldrich. Diglycolic anhydride and tetra-n-
butylammonium fluoride were purchased from Thermo Fisher Scientific (USA). 
SqMA was prepared according to published methods.
13
 N-tert-Butyl-N-(1-
diethyl phosphono-2,2-dimethylpropyl)nitroxide (SG1, 86%) was kindly 
provided by Arkema. The AMA-SG1 (2-(N-tert-butyl-N-(1-diethoxyphosphoryl-
2,2-dimethylpropyl) aminoxy)propionic acid)alkoxyamine was prepared 
according to a published method.
27
 CdA-AMA-SG1, CdA-digly-AMA-SG1, 
digly-AMA-SG1, CdA-CDPA, CdA-digly-CDP, digly-CDP, and Napht-AMA-
SG1 were prepared as reported elsewhere.
23-26
 LysoTracker Red was purchased 
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from Life Technologies. Dulbecco’s modified Eagle’s medium (DMEM), fetal 
bovine serum (FBS) and human serum were purchased from Sigma (France). 
Penicillin was purchased from Lonza (Verviers, Belgium). All other materials 
were purchased from Sigma-Aldrich at the highest available purity and used as 
received.  
Synthesis 
Polymerization of isoprene from CdA-AMA-SG1. CdA-AMA-SG1 (55 mg, 
0.075 mmol) was placed in a 15-mL-capacity pressure tube (Ace Glass, Model 
8648-164) fitted with plunger valves and thermowells. Isoprene (0.75 mL, 7.5 
mmol) and dioxane (0.75 mL) were added and the tube was subjected to three 
freeze-pump-thaw cycles, then backfilled with argon. The tube was placed in an 
oil bath at 115 °C for 2 h (PI1), 8 h (PI2), or 16 h (PI3) and then cooled to room 
temperature by placing them in a cold-water bath. The residue was concentrated 
under reduced pressure to give CdA-polyisoprene (PI) as a colorless product. 
Another polymerization was performed for 16 h with [isoprene]0/[CdA-AMA-
SG1]0 = 200/1 (PI4). 
Polymerization of isoprene from CdA-digly-AMA-SG1. CdA-digly-AMA-
SG1 (54 mg, 0.06 mmol) was placed in a 15-mL-capacity pressure tube (Ace 
Glass, Model 8648-164) that was fitted with plunger valves and thermowells. 
Isoprene (0.6 mL, 6.0 mmol) and dioxane (0.6 mL) were added, and the tubes 
were subjected to three freeze-pump-thaw cycles, then backfilled with argon. 
The tubes were placed in an oil bath at 115 °C for 4 h (PI1d) or 16 h (PI2d) and 
then cooled to room temperature by placing them in a cold-water bath. The 
residue was concentrated under reduced pressure to give CdA-digly-PI as a 
colorless product. Two other polymerizations were performed for 16 h with 
[isoprene]0/[CdA-digly-AMA]0 = 200/1 (PI3d) and 400/1 (PI4d). 
Polymerization of SqMA from CdA-CDPA. CdA-CDPA (31.8 mg, 0.04 
mmol), AIBN (2.3 mg, 0.014 mmol), SqMA (0.11 g, 0.24 mmol) and dioxane 
(0.75 mL) were mixed together and equally distributed among four 7 mL glass 
vials. The solutions were degassed with argon bubbling for 30 min. The tubes 
were placed in an oil bath at 70 °C for 0.5 h (PSq1), 1 h (PSq2), 2 h (PSq3) or 
22 h (PSq4), and then cooled to room temperature by placing them in a cold-
water bath. For each polymer, the residue was concentrated under reduced 
pressure and precipitated in cold MeOH to give protected CdA-PSqMA as a 
yellow viscous liquid. 
Polymerization of SqMA from CdA-digly-CDP. CdA-digly-CDP (52.5 mg, 
0.06 mmol), AIBN (1.2 mg, 0.007 mmol), SqMA (0.16 g, 0.36 mmol) and 
dioxane (0.8 mL) were mixed together and equally distributed among three 7 
mL glass vials. The solutions were degassed with argon bubbling for 30 min. 
The tubes were then placed in an oil bath at 70 °C for 1 h (PSq2d), 4 h (PSq3d) 
 Drug-Initiated.docx Printed 05/11/2019  5 
and 30 h (PSq4d) and then cooled to room temperature by sinking them in a 
cold-water bath. For each polymer, the residue was concentrated under reduced 
pressure and precipitated in cold MeOH to give protected CdA-digly-PSqMA as 
a yellow viscous liquid. Another polymerization was performed for 4 h with 
[SqMA]0/[CdA-digly-CDP]0 = 3/1 (PSq1d). 
Polymerization of isoprene from Napht-AMA-SG1. Napht-AMA-SG1 (38.7 
mg, 0.056 mmol) was placed in a 15 mL capacity pressure tube (Ace Glass 
8648-164) fitted with a plunger valve and a thermowell. Isoprene (PN1: 2.4 mL, 
23.1 mmol; PN2: 1.2 mL, 11.5 mmol) and dioxane (PN1: 2.4 mL; PN2: 1.2 mL) 
were added and the tube was subjected to three freeze-pump-thaw cycles, then 
backfilled with argon. The tube was placed in an oil bath at 115°C for 18 h and 
then cooled down to room temperature by placing the tube in a cold-water bath. 
The residue was concentrated under reduced pressure and precipitated in MeOH 
to give Napht-PI as a yellow viscous liquid. 
Deprotection of TBDMS protected polymer prodrugs. TBDMS-protected 
CdA-PI, CdA-digly-PI, CdA-PSqMA, or CdA-digly-PSqMA (100 mg) was 
dissolved in 0.5 mL of THF, then tetra-n-butylammonium fluoride (1 M in THF, 
50 μL) was added and the solution continued to be stirred for 15 min before 
precipitation into 10 mL of MeOH and storage at 4°C for 36 h. The purified 
polymer was then collected by centrifugation, dried under high vacuum and 
analyzed by 
1
H NMR and SEC. 
1
H NMR analysis showed a complete 
disappearance of TBDMS protecting groups. 
Analytical Methods 
Nuclear magnetic resonance spectroscopy (NMR). NMR spectroscopy was 
performed in 5 mm-diameter tubes in CDCl3 or DMSO-d6 at 25 °C. 
1
H and 
13
C 
NMR spectroscopy was performed on a Bruker Avance 300 spectrometer at 300 
MHz (
1
H) or 75 MHz (
13
C). The chemical shift scale was calibrated on the basis 
of the internal solvent signals. 
Mass spectrometry (MS). Mass spectra were recorded with a Bruker 
Esquire-LC instrument. 
Size exclusion chromatography (SEC). SEC was performed at 30 °C with 
two columns from Polymer Laboratories (PL-gel MIXED-D; 300 mm × 7.5 mm; 
bead diameter = 5 mm; linear part, 400 to 4 × 10
5
 g mol
-1
) and a differential 
refractive index detector (SpectraSystem RI-150 from Thermo Electron Corp). 
The eluent was chloroform at a flow rate of 1 mL min
-1
 (Waters 515 pump) and 
toluene was used as a flow-rate marker. In the case of PI, the calibration curve 
was based on polystyrene (PS) standards (peak molar masses, Mp = 162−523 
000 g mol−
1
) from Polymer Laboratories. A PI calibration curve was constructed 
by converting the PS standard peak molecular weights (MPS) to PI molecular 
weights (MPI) using Mark−Houwink−Sakurada (MHS) constants determined for 
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both polymers in CCl4 at 25 °C. For PI, the MHS constants used were KPI = 2.44 
× 10
4
 and αPI = 0.712. For PS, KPS = 7.1 × 10
4
 and αPS = 0.54 (MW < 16 700 g 
mol
-1
) or KPS = 1.44 × 10
4
 and αPS = 0.713 (MW > 16 700 g mol
-1
).
28
 In the case 
of PSqMA, the calibration curve was based on polymethyl methacrylate 
(PMMA) standards (peak molar masses, Mp = 625–625 500 g mol
−1) from 
Polymer Laboratories. This technique allowed the number-average molar mass 
(Mn), the weight-average molar mass (Mw) and the dispersity (Đ = Mw/Mn) to be 
determined. 
Dynamic light scattering (DLS) and zeta potential. Nanoparticle diameters 
(Dz) and zeta potentials (ζ) were measured by DLS with a Nano ZS from 
Malvern (scattering angle = 173°) at a temperature of 25 °C. The surface charge 
of the nanoparticles was investigated by ζ-potential (mV) measurement at 25 °C 
after dilution with 1 mM NaCl, using the Smoluchowski equation. For long-term 
colloidal stability studies, nanoparticles were stored at 4 °C between each 
measurement. 
Cryogenic transmission electron microscopy (cryo-TEM). The morphology 
of the different nanoassemblies was examined by cryo-TEM. Briefly, 5 μL of 
the nanoparticle suspension (5 mg mL
-1
) was deposited on a lacey 
formvar/carbon 300 mesh copper microscopy grid (Ted Pella). Most of the drop 
was removed with blotting filter paper and the residual thin film remaining 
within the holes was vitrified by plunging into liquid ethane. Samples were then 
observed using a JEOL Model 2100HC microscope. 
Fluorescence spectroscopy. Emission spectra were obtained using a LS 50B 
fluorescence spectrometer from PerkinElmer. All measurements were conducted 
at room temperature (∼25 °C).  
Nanoparticle Preparation  
Nanoparticles were prepared by the nanoprecipitation technique. Unless 
otherwise mentioned, a final nanoparticle concentration of 2.5 mg mL
-1
 was 
targeted. Briefly, 2.5 mg of polymer was dissolved in 0.5 mL of THF and added 
dropwise to 1 mL of MilliQ water under stirring. THF was then evaporated at 
room temperature using a Rotavapor (Buchi). Average diameter (Dz) and zeta 
potential measurements were carried out in triplicate. For the co-
nanoprecipitation of Napht-PI/CdA-digly-PI, 2.23 mg of PI4d and 0.27 mg of 
PN2 were dissolved in 0.5 mL of THF. A similar procedure was then applied. 
The resulting PN2/PI4d nanoparticles had a composition of 10.8 wt.% PN2 and 
89.2 wt.% PI4d, thus giving an overall drug loading of 5.3 wt.%.  
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Biological Evaluations 
Cell lines and cell culture. The murine leukemia L1210 cells were kindly 
provided by Dr Lars Petter Jordheim (INSERM U590, Université Claude 
Bernard Lyon I, Lyon, France), and maintained as recommended. Briefly, 
L1210 cells were cultured in DMEM. All media were supplemented with 10% 
heat-inactivated FBS (56 °C, 30 min) and penicillin (100 U mL−
1
). Cells were 
maintained under a humid atmosphere at 37 °C with 5% CO2. 
In vitro anticancer activity. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] was used to test cytotoxicity of polymer prodrug 
nanoparticles and cell viability. Briefly, L1210 cells (5 × 10
3
 per well) were 
seeded in 96-well plates. After 1 h of incubation, cells were exposed to a series 
of different concentrations of polymer prodrug nanoparticles or free CdA for 72 
h. After exposure, the medium was added with 20 μL of MTT solution (5 mg 
mL−
1
 in PBS) to each well. The plates were incubated for 1 h at 37 °C and the 
medium was removed after centrifugation (200g, 5 min, 25 °C). 200 μL of 
DMSO were then added to each well to dissolve the formazan crystals. 
Absorbance was measured at 570 nm using a plate reader (Metertech Σ 960, 
Fisher Bioblock, Illkirch, France). The percentage of surviving cells was 
calculated as the absorbance ratio of treated to untreated cells. The inhibitory 
concentration 50% (IC50) of the treatments was determined from the dose–
response curve. All experiments were set up in sextuplicate to determine means 
and SDs. 
Cell imaging. L1210 cells were cultured on a coverslip in a culture dish for 
24 h to achieve confluence. Cells were then incubated with the fluorescent 
nanoparticles at a concentration of 20 μg.mL-1 at 37 °C for 24 h, then incubated 
with LysoTracker Red for 30 min under same incubation conditions. After 
treatment, the cells were washed with Dulbecco’s phosphate buffered saline 
(PBS) and imaged using a confocal (SP8 TCS Leica, Germany) with a 63X/1.4 
oil-immersion objective. The excitation wavelength was 405 nm and 543 nm, 
and the fluorescence was collected in the range of 415–530 nm and 569–682 
nm, respectively. The pinhole diameter was set to 1 Airy Unit. 
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Results and Discussion 
Design and Synthesis of CdA-Based Polymer Prodrugs 
Two different RDRP techniques (i.e., NMP or RAFT polymerization) were 
employed to prepare CdA-polymer prodrugs because of their well-known 
advantages in terms of simplicity and robustness to achieve well-defined 
functional polymers. Two CdA-bearing alkoxyamines and two CdA-bearing 
CTAs were synthesized, with either ester (linear or -methyl substituted) or 
diglycolate linkers in between the drug and the RDRP moiety (Figure 2). 
Because of the poor reactivity of the C-6 amino group of CdA, the secondary 
hydroxyl group was selectively functionalized with the alkoxyamines or the 
RAFT agents, after protection of the primary hydroxyl group by tert-
butyldimethylsilyl chloride (TBDMSCl). The functionalization was achieved by 
EDC/DMAP-assisted esterification with two SG1-based alkoxyamines (i.e., 
AMA-SG1 and digly-AMA-SG1) or two trithiocarbonates (4-cyano-4-
[(dodecylsulfanylthiocarbonyl) sulfanyl]pentanoic acid (CDPA) and diglycolate 
4-cyano-4-[(dodecylsulfanylthiocarbonyl)sulfanyl]pentanol (digly-CDP)). To 
position a diglycolate linker in between the drug and the RDRP moiety to 
enhance the drug release kinetics, AMA-SG1 and CDP were previously reacted 
with diglycolic anhydride, giving digly-AMA-SG1 and digly-CDP. The 
coupling yields ranged from 47% to 91% (those with the diglycolate linker gave 
higher yields, likely because of a lower steric hindrance). 
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Figure 2. Structures of cladribine-polyisoprene (CdA-PI, PIx), cladribine-
diglycolate-polyisoprene (CdA-digly-PI, PIxd), cladribine-poly(squalenoyl 
methacrylate) (CdA-PSqMA, PSqx) and cladribine-diglycolate-poly(squalenoyl 
methacrylate) (CdA-digly-PSqMA, PSqxd). 
Two different polymer promoieties, polyisoprene (PI) and poly(squalene 
methacrylate) (PSqMA), were selected. Given its chemical degradability,
29
 as 
well as its biocompatibility
30
 and its structural similarity with natural terpenoids, 
PI was chosen for the design of CdA-based polymer prodrugs by NMP. Because 
of the wide application of squalene (Sq) as building block for the construction of 
molecular prodrugs,
31,32
 SqMA,
13
 a methacrylate monomer with a pendant 
squalene moiety was chosen for the design of CdA-based polymer prodrugs by 
RAFT polymerization. NMP of isoprene in presence of either CdA-AMA-SG1 
or CdA-digly-AMA-SG1, was performed at 115 °C in dioxane, followed by 
deprotection of TBDMS groups by tetra-n-butylammonium fluoride (TBAF) to 
give the CdA-PI (PIx, x = 1–4) and CdA-digly-PI (PIxd, x = 1–4) conjugates, 
 Drug-Initiated.docx Printed 05/11/2019  10 
respectively (Figure 2). The RAFT polymerization of SqMA in presence of 
either CdA-CDPA or CdA-digly-CDP, was carried out in 1,4-dioxane at 70 °C 
with AIBN as the initiator, resulting in CdA-PSqMA (PSqx, x = 1–4) and CdA-
digly-PSqMA (PSqxd, x = 1–4) prodrugs after similar deprotection, respectively 
(Figure 2).  
By varying the polymerization time and/or the [monomer]0/[functionalized 
CdA]0 ratio, a library of well-defined CdA-based polymer prodrugs with 
variable chain lengths was obtained. Excellent control over the molecular weight 
of the polymers by both NMP and RAFT polymerizations was observed. The 
resulting polymerizations exhibited a linear relationship between monomer 
conversion and Mn, with values close to theory. All polymer prodrugs were 
characterized by 
1
H NMR and SEC, and the Mn ranged from 1420 g mol
-1
 to 
4980 g mol
-1
, whereas CdA drug loading varied from 5.7 wt.% to 20.1 wt.%. It 
should be noted that, the drug loading could easily be adjusted by changing the 
polymer chain length, one of the feature of the drug-initiated approach. 
Table 1 Macromolecular and Colloidal Characteristics of CdA-PI, CdA-
digly-PI, CdA-PSqMA and CdA-digly-PSqMA Polymer Prodrug 
Nanoparticles 
Expt. Mn
a 
(g.mol
-1
) 
DPn,SEC
b
 Ð
a 
 
Dz
c 
(nm) 
PSD
c 
d 
(mV) 
%CdA
e
 
(wt.%) 
PI1 1420 12 1.17 167 0.06 -69 20.1 
PI2 1560 14 1.09 201 0.12 -70 18.3 
PI3 2270 24 1.15 152 0.08 -64 12.6 
PI4
f
 2520 28 1.14 137 0.10 -71 11.3 
PI1d 1470 10 1.10 143 0.07 -66 19.4 
PI2d 1710 16 1.13 128 0.10 -68 16.7 
PI3d
f
 2960 34 1.17 127 0.08 -70 9.6 
PI4d
g
 4980 64 1.20 111 0.11 -66 5.7 
PSq1 2710 4 1.18 69 0.14 -51 10.5 
PSq2 3080 5 1.16 82 0.11 -54 9.3 
PSq3 3420 6 1.17 94 0.11 -58 8.3 
PSq4 4040 7 1.12 94 0.09 -61 7.1 
PSq1d
h
 2920 4 1.25 112 0.12 -62 9.8 
PSq2d 3090 5 1.25 107 0.14 -60 9.2 
PSq3d 3310 6 1.27 96 0.12 -54 8.6 
PSq4d 4470 8 1.27 84 0.10 -53 6.4 
aDetermined by SEC. bCalculated according to DPn,SEC = (Mn,SEC – MWalkoxyamine + 
MWTBDMS) / MWisoprene for PI and DPn,SEC = [Mn,SEC – (MWCTA – MWTBDMS)] / MWSqMA 
for PSqMA. cDetermined by DLS. dZeta potential. e%CdA = MWCdA / Mn,SEC. 
f[isoprene]0/[alkoxyamine]0 = 200/1. 
g[isoprene]0/[alkoxyamine]0 = 400/1. 
h[SqMA]0/[CTA]0 = 3/1, for the other PSqMA polymers [SqMA]0/[CTA]0 = 6/1.  
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Formulation and Colloidal Characteristics of the Nanoparticles 
CdA-based polymer prodrug nanoassemblies were prepared by 
nanoprecipitation of a THF solution of the different CdA-based polymer 
prodrugs into water, targeting a final concentration of 2.5 mg mL
-1
. As shown in 
Table 1, the nanoparticles exhibited an average diameters in the 70−200 nm 
range and narrow particle size distributions (PSD = ca. 0.1) as measured by 
DLS. Representative Cryo-TEM images of each type of nanoparticles showed 
spherical morphologies and colloidal characteristics in good agreement with 
DLS data (Figure 3). 
 
 
    
Figure 3. Cryo-TEM images of: (a) CdA-PI PI3, (b) CdA-digly-PI PI4d, 
(c)CdA-PSqMA PSq1 and (d) CdA-digly-PSqMA PSq1d nanoparticles. 
The colloidal characteristics of the different polymer prodrug nanoparticles 
were then monitored at room temperature with time; from 3 weeks to 3 months. 
As shown in Figure 4, they all exhibited very high colloidal stability in water in 
terms of average diameter and particle size distribution. The high stability is 
likely the result of an efficient electrostatic stabilization provided by the strongly 
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negative surface charges (from − 70 mV to − 50 mV) of the different 
nanoparticles, as shown by zeta potential measurements (Table 1). Interestingly, 
the average diameter can be accurately tuned by varying the polymer chain 
length: the longer the chain length, the smaller the diameter. With CdA-digly-PI 
for example, the average diameter decreased from 143 nm to 111 nm along with 
increasing the Mn from 1470 g mol
-1
 to 4980 g mol
-1
 (PI1d−PI4d) (Table 1). 
This trend could be assigned to an increasing compaction of the polymer chains 
when the Mn is increased because of increased hydrophobic interactions and 
lower solubility.  
 
 
Figure 4. Evolution with time of the average diameter (solid symbols) and the 
particle size distribution (open symbols) determined by DLS of: (a) CdA-PI (PI1 
and PI3) and CdA-digly-PI (PI1d−PI4d) nanoparticles and (b) CdA-digly-
PSqMA (PSq1d–PSq4d) nanoparticles. 
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In Vitro Anticancer Activity  
The in vitro cytotoxic activity of the different polymer prodrug 
nanoparticles was then investigated by cell viability assay (MTT) on a murine 
leukemia (L1210) cell line (see Figure 5). On one hand, CdA-PI nanoparticles 
did not show any cytotoxicity up to 10 μM, even when the incubation time was 
increased from 3 days to 5 days, whereas CdA-digly-PI nanoparticles 
(PI1d−PI4d) with Mn ranging from 1470 g.mol
-1
 to 4980 g.mol
-1
 led to 
significant cytotoxicity (Figure 5a) with half maximal inhibitory concentrations 
(IC50) varying between 660 nM and 1430 nM. These results are in line with the 
drug release profiles of the different CdA-based prodrugs
23,24
 and also with 
previous literature about small CdA prodrug molecules.
33,34
 The nanoparticles 
from control polymer AMA-digly-PI (PI0d) (Mn = 2650 g mol
−1) didn’t give any 
cytotoxicity up to at least ∼6 μM. On the other hand, all PSqMA-based prodrug 
nanoparticles exhibited from moderate to significant anticancer acitivity (Figure 
5b). For instance, CdA-digly-PSqMA nanoparticles PSq1d, PSq3d and PSq4d 
(Mn = 2920, 3310 and 4470 g.mol
-1
, respectively) gave IC50 values regularly 
decreasing from 2.17 to 1.36 µM. However, the cytotoxicity of CdA-PSqMA 
nanoparticles was much lower than that of CdA-digly-PSqMA. PSq1, PSq3 and 
PSq4 (Mn = 2710, 3420 and 4040 g.mol
-1
, respectively) indeed showed IC50 
values gradually ranging from 4.1 µM to 8 µM.  
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Figure 5. Viability assay (MTT test) on L1210 cells with increasing 
concentrations of: (a) CdA-digly-PI nanoparticles PI1d–PI4d and PI0 (AMA-
digly-PI) and free CdA and (b) CdA-digly-PSqMA nanoparticles PSq1d, PSq3d 
and PSq4d, CdA-PSqMA nanoparticles PSq1, PSq3 and PSq4 and free CdAs. 
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CdA-based polymer prodrug nanoparticles showed higher IC50 values than 
free CdA (IC50 = 145 nM), because of their prodrug nature, but high 
cytotoxicity to cancer cells was still obtained. Interestingly, for both of PI- and 
PSqMA-based systems, IC50 values decreased with increasing the polymer 
chain length (Figure 5). Several parameters are known to strongly influence the 
cellular uptake of the nanoparticles by cancer cells (and eventually the 
cytotoxicity), such as their average size and the composition of their corona. 
Whereas smaller nanoparticles usually give a better internalization in cancer 
cells, increasing the polymer chain length is likely to result in more hydrophobic 
nanoparticle surfaces, leading to a different protein adsorption pattern, and 
eventually change the nanoparticle uptake by cancer cells.
35,36
 From all these 
results, a structure-cytotoxicity relationship was then established (Table 2). A 
decrease of cytotoxicity to cancer cells was observed in the following order: 
CdA-digly-PI > CdA-digly-PSqMA > CdA-PSqMA >> CdA-PI (data for CdA-
PI was not plotted because no cytotoxicity was obtained). Not only this can be 
assigned to the lability of the linker (diglycolate > linear ester > methyl-
substituted ester), but also to the nature of the monomer used (CdA-digly-PI > 
CdA-digly-PSqMA). Indeed, PI chains are likely to provide less steric hindrance 
than bulky PSqMA chains, thus giving more accessibility for the cleavage to 
proceed.  
Table 2 Evolution of the IC50 as Function of the Nature and the Mn of the 
CdA-Based Polymer Prodrug.
a
 
Expt. Mn (g.mol
-1
) IC50
 
(M) 
CdA-PI 
  
n.d. n.d. 
  
CdA-digly-PI 
4470 1.36 
3310 2.20 
2920 2.17 
CdA-PSqMA 
4040 4.10 
3420 7.0 
2710 8.0 
CdA-digly-PSqMA 
4980 0.66 
2960 0.72 
1710 1.43 
a
Note that CdA-PI is not represented because the IC50 was impossible to 
determine because of absence of CdA release. 
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Fluorescence Imaging in Living Cells 
To study the subcellular localization of CdA-based polymer nanoparticles in 
living cells, a fluorescent polymer (Napht-PI PN2, Mn = 3700 g.mol
-1
, Ð = 
1.15)
26
 exhibiting aggregation-induced emission (AIE) activity
25
 was 
synthesized following a similar strategy and co-nanoprecipitated with CdA-
based polymer prodrugs. L1210 cells were then incubated with fluorescent 
nanoparticles obtained by the co-nanoprecipitation of PN2 and PI3d. As shown 
in Figure 6, a bright green fluorescence signal from the nanoparticles (green 
channel, 500–560 nm, λex = 408 nm) was observed in L1210 cells, which 
indicated the efficient internalization of the nanoparticles into the cells. The 
presence of the nanoparticles in the lysosomes was confirmed by a yellow 
colocalization observed after overlaying the green channel with the red channel 
(staining of the lysosomes, 569−682 nm, λex = 543 nm) (Figure 6d), which 
suggested an endocytosis mechanism. Importantly, cytotoxicity to cancer cells 
was maintained as shown by MTT assay (whereas pure PN2 nanoparticles were 
not toxic to cells).
26
 This general strategy enabled the facile production of AIE 
dye-based polymers for nanoparticle labeling by simple co-nanoprecipitation 
with drug-polymer conjugates. 
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Figure 6. L1210 cells Normarski image (a), confocal microscopy images [green 
channel (Napht, b), red channel (LysoTracker Red, c)] and merge of red and 
green fluorescence images with Nomarski image (d) after a 24 h incubation of 
L1210 cells with AIE-active polymer prodrug nanoparticles (PI3d/PN2, 1 wt.% 
of Napht-OH). Scale bars = 20 µm. Arrows indicate colocalization. 
Conclusion 
Different libraries of CdA-based polymer prodrugs were successfully 
synthesized by the “drug-initiated” method via either NMP of isoprene or RAFT 
polymerization of a methacrylic ester bearing a naturally occurring isoprenoid 
moiety. The formed nanoparticles obtained by nanoprecipitation exhibited great 
colloidal stability in aqueous solution and in vitro cytotoxicity to cancer cells 
governed by their structural parameters. With the help of fluorescent 
nanoparticles from AIE-dye-initiated polymerization, the subcellular 
localization of CdA-based polymer nanoparticles was also successfully imaged 
in living cells. This study opens new perspectives for the design of a broad range 
of novel drug-initiated polymer prodrug nanocarriers by changing the nature of 
the drug, the linker and the polymer. 
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